Regulatory Education for Industry: 2019 Complex Generic Drug Product Development Workshop – Sep. 25-26, 2019 - 09/25/2019

19th Nov, 2025

What's New: Drugs

FDA

Published By: FDA

What's New: Drugs

15th Jan, 2026

FDA

Completed PDUFA VII Deliverables

What's New: Drugs

15th Jan, 2026

FDA

Guiding Principles of Good AI Practice in Drug Development

What's New: Drugs

15th Jan, 2026

FDA

CDER SBIA YouTube Learning Library

What's New: Drugs

13th Jan, 2026

FDA

Apetamin — An Illegally Imported Weight Gain, Figure Augmentation Product

What's New: Drugs

13th Jan, 2026

FDA

FDA Approves First Treatment for Children With Menkes Disease

What's New: Drugs

13th Jan, 2026

FDA

FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications

What's New: Drugs

13th Jan, 2026

FDA

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity

Regulatory Education for Industry: 2019 Complex Generic Drug Product Development Workshop – Sep. 25-26, 2019 - 09/25/2019

Related Articles

Completed PDUFA VII Deliverables

Guiding Principles of Good AI Practice in Drug Development

CDER SBIA YouTube Learning Library

Apetamin — An Illegally Imported Weight Gain, Figure Augmentation Product

FDA Approves First Treatment for Children With Menkes Disease

FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity

Regulatory Education for Industry: 2019 Complex Generic Drug Product Development Workshop – Sep. 25-26, 2019 - 09/25/2019

Related Articles

Completed PDUFA VII Deliverables

Guiding Principles of Good AI Practice in Drug Development

CDER SBIA YouTube Learning Library

Apetamin — An Illegally Imported Weight Gain, Figure Augmentation Product

FDA Approves First Treatment for Children With Menkes Disease

FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity